Nebenwirkungen · Tepadina
TEPADINA 15 mg powder for concentrate for solution for infusion TEPADINA 100 mg powder for concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 11
HOS-210404 · Präparat HOS-154509
The adverse reactions considered at least possibly related to conditioning treatment including thiotepa, reported in paediatric patients as more than an isolated case, are listed below by system organ class and by frequency. Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness. Frequencies are defined as: very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1,000 to <1/100), rare (≥1/10,000 to <1/1,000) very rare (<1/10,000), not known (cannot be estimated from the available data).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-02-24T14:00:00Z · SHA-256 42c8bab87a55159cb982d55f577a064273549ce149f75b75dbf4d5650be413bc · Passage 68167951cb6fcc2581d4970324a8ba42854d6d0425a220a9e2bc24a4fdebabcc · Zeichen 7534–8075 im Abschnitt